GlassScriptPhysician profile
Thomas W Miller
NPI 1386725638
$4,944.61
in general payments reported to CMS, 2019-2025
45 companies · $1,604 in 2025
The $1,604 reported for 2025 was more than what 84% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.02 · 2020: $50.45 · 2021: $435 · 2022: $746 · 2023: $922 · 2024: $1,160 · 2025: $1,604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,685.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $920.31 | 2021-2025 | |
| Lilly USA, LLC | $507.77 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $311.16 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $299.01 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $295.28 | 2022-2025 | |
| Amgen INC. | $227.03 | 2021-2025 | Repatha, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.67 | 2019-2025 | Jardiance |
| Abbott Laboratories | $186.20 | 2021-2025 | Freestyle Libre 3, Eterna |
| Axsome Therapeutics, INC. | $165.35 | 2023-2025 | Auvelity |
| Exact Sciences Corporation | $144.06 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $140.05 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $132.61 | 2021-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $128.51 | 2022-2025 | Airsupra, Breztri |
| Jazz Pharmaceuticals INC. | $126.32 | 2023-2025 | |
| Astellas Pharma US INC | $104.24 | 2023-2025 | Veozah |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.